p27(Kip1) Is the key mediator of phenylacetate induced cell cycle arrest in human prostate cancer cells

Anticancer Research

Volumn 20, Issue 5, 2000, Pages 3075-3081

  Onishi, T ^a   Yamakawa, K ^a   Franco, O E ^a   Suzuki, R ^a   Kawamura, J ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell cycle; p27(Kip1); Phenylacetate; Prostate cancer

Indexed keywords

ANDROGEN; CYCLIN D1; CYCLIN E; PHENYLACETIC ACID; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; ANTISENSE OLIGONUCLEOTIDE; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; PHENYLACETIC ACID DERIVATIVE; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CYTOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DRUG EFFECT; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; G1 PHASE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PHENYLACETATES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0033623331     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Studies on prostate cancer. I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
2. Carcinoma of the prostate
3. Phenylacetic acid in human body fluids: High concentration between plasma and cerebrospinal fluid concentrations values
4. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate
5. Phenylacetate: A novel nontoxic inducer of tumor cell differentiation
6. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
7. In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate
8. Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate
9. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells
10. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
11. Phase I study of phenylacetate administered twice daily to patients with cancer
12. Braking the cell cycle
13. Mammalian G1 cyclins
14. The retinoblastoma protein and cell cycle control
15. Inhibitors of mammalian G1 cyclin-dependent kinases
16. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation
17. Requirement of p27(Kip1) for restriction point control of the fibloblast cell cycle
18. IL-2 mediated elimination of the p27(Kip1) cyclin-Cdk Kinase inhibitor prevented by rapamicin
19. p27(Kip1) A cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest
20. p27, A novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
21. Regulation of cyclin E and p27(Kip1) during mitosis in BALB/c 3T3 cells
22. Rapamycin resistance tied to defective regulation of p27(Kip1)
23. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27(Kip1)) of cyclin-dependent kinase 4 activation
24. Abrogation of p27(Kip1) by cDNA antisense suppresses quiescence (G0 state) in fibroblasts
25. Human cyclin E, a nuclear protein essential for the G1 to S phase transition
26. Formation and activation of a cyclin E-cdk 2 complex during the G1 phase of the human cell cycle
27. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
28. Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma
29. Involvement of p27(Kip1) in G1 arrest by high dose 5α-dehydrotestosterone in LNCaP human prostate cancer cells
30. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade
31. Association of p27(Kip1) levels with recurrence and survival in patients with stage C prostate carcinoma
32. Expression of p27(Kip1) in prostatic adenocarcinoma
33. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
34. Distinct altered patterns of gene expression in benign prostatic hyperplasia and prostatic carcinoma
35. Up-regulation and functional role of p21(Waf1/Cip1) during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate
36. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter
37. WAF1, a potential mediator of p53 tumor suppressor
38. p53 Cell cycle control and apoptosis: Implication for cancer